When pharmacotherapy for hyperglycemia is necessary, our expert recommendations address the specific pathophysiology of pasireotide-induced hyperglycemia by recommending the incretin-based therapeutics GLP-1 RA and DPP-4i as first-line therapy in all appropriate patients as an alternative to metformin. Here, GLP1R is linked to Hyperglycemia.